机器人辅助部分肾切除术治疗大体积肾肿瘤:多中心系列研究
cT2a组手术时间、估计出血量和缺血时间增加,出院时急性肾损伤风险升高,复发风险更高,但并发症、切缘阳性率、住院时间和24个月肾功能下降无差异。
要点
- cT2a肿瘤行RAPN的手术时间和出血量高于cT1a,但并发症与切缘阳性率无差异
- cT2a组出院时急性肾损伤风险升高,12个月无复发生存率显著低于T1组
- RAPN用于cT2a需选择患者并由经验丰富术者实施,需延长随访评估长期生存
核心结论
- 对于cT2a肿瘤,在经验丰富术者及具备术后并发症处理能力的机构中,RAPN是经过选择患者人群的可行治疗选择。
- 尽管cT2a组出血量更多、手术和缺血时间更长,但并发症率和切缘阳性率与T1肿瘤相比无差异。
- 术后24个月肾功能保存率相当,但cT2a组12个月无复发生存率显著更低,需延长随访。
研究设计与样本
- 采用多变量回归模型(线性、逻辑、泊松等)比较cT2a与cT1a、cT1b的术中和术后结局,并调整术者和排除半径成分的改良R.E.N.A.L.肾测量评分。
主要发现
- cT1a、cT1b和cT2a肿瘤中位大小分别为2.5、5.0和8.0 cm(P < 0.001),改良R.E.N.A.L.评分分别为6.0、6.5和7.0(cT1a,P < 0.001;cT1b,P = 0.105)。
- cT2a vs cT1a:手术时间增加12%(P < 0.001),估计出血量增加32%(P < 0.001),缺血时间增加7%(P = 0.008),出院时急性肾损伤比值比为3.93(95%CI 1.33,8.76;P = 0.009),复发风险更高(HR 10.9,95%CI 1.31,92.2;P = 0.027)。
- cT2a vs cT1b:出血量增加12%(P = 0.036),手术时间增加5%(P = 0.062),复发风险边缘性升高(HR 11.2,95%CI 0.77,11.5;P = 0.059)。
- cT2a组与cT1a、cT1b组在并发症(P = 0.535;P = 0.382)、切缘阳性(P = 0.972;P = 0.681)、住院时间(P = 0.507;P = 0.513)及术后24个月肾功能下降(P = 0.124;P = 0.467)方面无差异。
关键数值与推荐
- cT2a定义为肿瘤大小7至<10 cm,本组中位大小8.0 cm。
- cT2a vs cT1a的复发风险HR 10.9(95%CI 1.31,92.2;P = 0.027)。
- cT2a vs cT1b的复发风险HR 11.2(95%CI 0.77,11.5;P = 0.059)。
临床怎么用
- 对经过选择的cT2a肾肿瘤患者,可由经验丰富术者在具备并发症处理能力的机构中考虑RAPN。
- 术前应告知cT2a患者出血量、手术时间和缺血时间增加及急性肾损伤风险升高,并重视术后复发监测。
- cT2a行RAPN后需延长随访以评估长期生存结局。
局限性
- cT2a组样本量仅41例,结果需谨慎解读。
- 为多中心回顾性数据库分析,存在选择偏倚,复发事件数有限导致置信区间较宽。
- 需延长随访进一步评估长期生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare peri-operative outcomes after robot-assisted partial nephrectomy (RAPN) for cT2a (7 to <10 cm) to cT1 tumours. MATERIALS AND METHODS: Patients with a cT1a (n = 1 358, 76.4%), cT1b (n = 379, 21.3%) or cT2a (n = 41, 2.3%) renal mass were identified from a multi-institutional RAPN database. Intra- and postoperative outcomes were compared for cT2a masses vs cT1a and cT1b masses using multivariable regression models (linear, logistic, Poisson etc.), adjusting for operating surgeon and a modified R.E.N.A.L. nephrometry score that excluded the radius component. RESULTS: The median sizes for cT1a, cT1b and cT2a tumours were 2.5, 5.0 and 8.0 cm, respectively (P < 0.001) with modified R.E.N.A.L. nephrometry scores being 6.0, 6.5 and 7.0, respectively (cT1a, P < 0.001; cT1b, P = 0.105). RAPN for cT2a vs cT1a masses was associated with a 12% increase in operating time (P < 0.001), a 32% increase in estimated blood loss (P < 0.001), a 7% increase in ischaemia time (P = 0.008), a 3.93 higher odds of acute kidney injury at discharge (95% confidence interval [CI] 1.33, 8.76; P = 0.009) and a higher risk of recurrence (hazard ratio [HR] 10.9, 95% CI 1.31, 92.2; P = 0.027). RAPN for cT2a vs cT1b masses was associated with a 12% increase in blood loss (P = 0.036), a 5% increase in operating time (P = 0.062) and a marginally higher risk of recurrence (HR 11.2, 95% CI 0.77, 11.5; P = 0.059). RAPN for cT2a tumours was not associated with differences in complications (cT1a, P = 0.535; cT1b, P = 0.382), positive margins (cT1a, P = 0.972; cT1b, P = 0.681), length of stay (cT1a, P = 0.507; cT1b, P = 0.513) or renal function decline up to 24 months post-RAPN (cT1a, P = 0.124; cT1b, P = 0.467). CONCLUSION: For T2a tumours RAPN is a feasible treatment option in a select patient population when performed by experienced surgeons in institutions equipped to manage postoperative complications. Although RAPN was associated with greater blood loss and longer operating and ischaemia time in T2a tumours, it was not associated with greater complication or positive surgical margin rates compared with T1 tumours. Renal function preservation rates were equivalent for up to 24 months postoperatively; however, 12-month recurrence-free survival was significantly lower in the T2a group. Extended follow-up is required to further evaluate long-term survival.
引用
- Delto JC, Paulucci D, Helbig MW, et al. Robot-assisted partial nephrectomy for large renal masses: a multi-institutional series. BJU Int. 2018. PMID: 29357404. doi:10.1111/bju.14139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。